| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4276967 | Urology Practice | 2016 | 9 Pages |
Abstract
Perioperative chemotherapy improves survival in patients with muscle invasive bladder cancer. Molecular predictors of the response to chemotherapy are still in the investigational phase and not yet incorporated into clinical practice. Thus, a risk adapted approach by reserving neoadjuvant chemotherapy for cisplatin eligible patients with high risk disease features may balance the benefits of neoadjuvant chemotherapy while minimizing overtreatment.
Keywords
methotrexate, vinblastine, doxorubicin and cisplatinMIBCNACMVACMRCgemcitabine and cisplatinEORTCEGFRPFsprogression-free survivaloverall survivalEuropean Organisation for Research and Treatment of CancerMuscle invasive bladder cancerUrinary bladder neoplasmsCMVCystectomyMedical Research CouncilAdjuvant chemotherapyChemotherapy, adjuvantNeoadjuvant chemotherapyMortalityestimated glomerular filtration rateneoadjuvant therapyPCRPathological complete response
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Samer L. Traboulsi, Wassim Kassouf,